FDA Approves New Dual-Mechanism Drug for Hyperuricemia Associated With Uncontrolled Gout

The FDA has approved a once-daily oral treatment of lesinurad and allopurinol (Duzallo, Ironwood Pharmaceuticals) for hyperuricemia associated with gout in patients who have not reached target serum uric acid (sUA) levels on allopurinol.

“The approval of Duzallo provides a new fixed-dose and dual-mechanism treatment option to help patients with uncontrolled gout achieve target serum uric acid levels. This represents an important and needed new option in the treatment of